Trending Alert: 4 HealthTech Tickers Trending Now

Names Inside If you cannot see this email properly, please click [here]( Powered by [HealthTechMovers.com]( Dear Reader, Below is a a list of 4 Healthtech Stocks that have appear to be trending by receiving buy ratings and showing positive investor sentiment, as well as news headlines. With that said, our editors are adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [How to profit from the new boom in gold]( Gold just passed $2,000/oz and is set for a new bull run in 2024. Now a renowned precious metals expert is sharing his No. 1 way to play it for just $5. [Click here for full details.]( --------------------------------------------------------------- [Exelixis, EXEL]( Summary: Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Jay Olson analyst at Oppenheimer reiterates coverage on [Exelixis (EXEL)](in the Health sector with a Buy rating and has set a price target of $29. [TipRanks.com]( reports that [Exelixis](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $28.20. In addition, TradingView issued a Sell rating for [EXEL]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on EXEL, please click here >>]( --------------------------------------------------------------- [CVRx, CVRX]( Summary: CVRx Inc. is a commercial-stage medical device company. It focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. CVRx Inc. is headquartered in Minneapolis, MN. Robbie Marcus analyst at J.P. Morgan reiterates coverage on [CVRx (CVRX)](in the Health sector with a Buy rating and has set a price target of $36. [TipRanks.com]( reports that [CVRx](currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $34.00. In addition, TradingView issued a Sell rating for [CVRX]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on CVRX, please click here >>]( --------------------------------------------------------------- Sponsor [Crypto millionaire makes stunning prediction...]( Wade – a man who's recommended 24 cryptos that have soared by as much as 1,000% or more – just released his latest prediction, and it has nothing to do with bitcoin, Ethereum, or any other cryptocurrency. But he says, "This could trigger the biggest moneymaking run since bitcoin." [Click here for the full details.]( --------------------------------------------------------------- [Vera Therapeutics, VERA]( Summary: Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. Justin Kim analyst at Oppenheimer reiterates coverage on [Vera Therapeutics (VERA)](in the Health sector with a Buy rating and has set a price target of $34. [TipRanks.com]( reports that [Vera Therapeutics](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $29.40. In addition, TradingView issued a Strong buy rating for [VERA]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on VERA, please click here >>]( --------------------------------------------------------------- [Resmed, RMD]( Summary: ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. The company currently has two operating segments, which are the Sleep and Respiratory Care segment and the Software-as-a-Service segment. Anthony Petrone analyst at Mizuho Securities reiterates coverage on [Resmed (RMD)](in the Health sector with a Buy rating and has set a price target of $195. [TipRanks.com]( reports that [Resmed](currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $181.20. In addition, TradingView issued a Strong buy rating for [RMD]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on RMD, please click here >>]( --------------------------------------------------------------- Sponsor ["Safe Investors Who Don't Get Out of Cash NOW Could Lose Everything Over the Next Six Months]( next six months are going to be some of the most precarious times to invest in the history of the United States. Because for the first time, your money is at risk of being completely wiped out, even when you think it is safest. This bubble is on a schedule and to get out before your portfolio becomes shark bait, you need to... [Watch This Video]( --------------------------------------------------------------- --------------------------------------------------------------- Sponsor [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [TipRanks.com]( tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [HealthTechMovers.com]( --------------------------------------------------------------- Sponsor [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- HealthTechMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software